Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 4:24 PM ET
Aurinia Pharmaceuticals Inc (AUPH) Statistics
Aurinia Pharmaceuticals (AUPH) has a market cap of $2.11B and an enterprise value of $2.06B. It kept 97.68% of revenue as net income over the last 12 months. Revenue grew 21.04% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.19% below the market cap, as cash exceeds debt.
| Market Cap | $2.11B |
|---|---|
| Enterprise Value | $2.06B |
| Latest price (Nov 17, 2026) | $15.40 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 30, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.4x and 3.1x.
| P/E Ratio | 15.1x |
|---|---|
| Forward P/E | 15.5x |
| P/S Ratio | 6.4x |
| Forward P/S | 6.4x |
| P/B Ratio | 3.1x |
| P/TBV Ratio | 3.1x |
| P/OCF Ratio | 11.9x |
| PEG Ratio | 0.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 12.0x EBITDA.
| EV / Earnings | 6.6x |
|---|---|
| EV / Sales | 6.4x |
| EV / EBITDA | 12.0x |
Price Statistics
The stock is up 0.33% over 52 weeks and trades 6.44% below its 50-day average.
| Beta (1Y) | 0.67 |
|---|---|
| 52-Week Change | +0.33% |
| 1-Month Change | -6.61% |
| 3-Month Change | -4.76% |
| 6-Month Change | -0.96% |
| 5-Year Change | -49.67% |
| 10-Year Change | +449.50% |
| Total Return (1Y) | +0.33% |
| Total Return (3Y CAGR) | +21.43% |
| Total Return (5Y CAGR) | -12.29% |
| Return vs SPY (1Y) | -12.20% |
| Max Drawdown (1Y) | -21.75% |
| Max Drawdown (3Y) | -49.32% |
| Sharpe Ratio (1Y) | -0.02 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $16.46 |
| 200-Day Average | $15.74 |
| 52-Week Range | $13.52 to $19.25 |
| RSI (14 Days) | 36.7 |
| Average Volume (20 Days) | 934.03K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.12x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.12x |
|---|---|
| Quick Ratio | 5.67x |
| Debt / Equity | 0.00x |
| Interest Coverage | 40.36x |
Returns and Efficiency
Return on equity is 47.80% over the last 12 months, against a 5-year average of -6.83%.
| Return on Equity (ROE) | 47.80% |
|---|---|
| Return on Assets (ROA) | 38.06% |
| ROE (5Y Average) | -6.83% |
| ROA (5Y Average) | -6.25% |
| ROIC (5Y Average) | 18.05% |
| Asset Turnover | 0.48x |
| Inventory Turnover | 0.68x |
| Receivables Turnover | 7.27x |
| Cash Conversion Cycle | 559 days |
Scores
AUPH has an Altman Z-Score of 8.13, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.13 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $321.74M over the last 12 months.
| Revenue | $321.74M |
|---|---|
| Revenue Growth (YoY) | +21.04% |
| Gross Profit | $291.57M |
| Operating Income | $156.37M |
| Pretax Income | $167.12M |
| Net Income | $314.27M |
| EBITDA | $167.24M |
| Reported EPS (TTM) | $1.02 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 79.63% of the $825.70M in total assets.
| Cash and Equivalents | $46.15M |
|---|---|
| Total Debt | $0 |
| Net Cash | $46.15M |
| Net Cash Per Share | $0.35 |
| Working Capital | $491.88M |
| Shareholder Equity | $657.52M |
| Book Value Per Share | $4.93 |
| Tangible Book Value | $654.35M |
| Tangible Book Per Share | $4.90 |
| Total Assets | $825.70M |
| Total Liabilities | $168.19M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $177.16M |
|---|---|
| FCF Per Share | $1.33 |
| Depreciation and Amortization | $27.83M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 48.60%, against a 5-year average of -99.33%.
| Gross Margin | 90.62% |
|---|---|
| Operating Margin | 48.60% |
| Pretax Margin | 51.94% |
| Net Margin | 97.68% |
| EBITDA Margin | 51.98% |
| Gross Margin (5Y Average) | 92.35% |
| Operating Margin (5Y Average) | -99.33% |
| Net Margin (5Y Average) | -83.61% |
Growth
Revenue grew 28.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | +28.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +41.38% |
| Book Value Per Share Growth (2Y CAGR) | +26.29% |
| Tangible Book Per Share Growth (2Y CAGR) | +26.72% |
Dividends and Yields
AUPH does not pay a dividend.
| Earnings Yield | 6.62% |
|---|---|
| Buyback Yield | 3.63% |
| Shareholder Yield | 3.63% |
Peer Position
Against 9 similar companies, AUPH has the 6th highest P/S.
P/S RatioPeer median 6.8x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +21.92%
| P/S Ratio | 6.4x vs 6.8x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +21.04% vs +21.92% median |
Analyst Forecast
Consensus estimates put revenue growth at 16.73% and EPS growth at 19.67% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +16.73% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +19.67% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AUPH
What is AUPH's market cap?
Aurinia Pharmaceuticals has a market cap of $2.11B. Its enterprise value, which adds debt and subtracts cash, is $2.06B.
What is AUPH's P/E ratio?
Aurinia Pharmaceuticals has a trailing P/E ratio of 15.1x and a forward P/E of 15.5x.
How many shares of AUPH are outstanding?
Aurinia Pharmaceuticals has 133.43M shares outstanding. The count is up 1.23% from a year earlier.
Does AUPH pay a dividend?
No. Aurinia Pharmaceuticals does not pay a dividend.
How much debt does AUPH have?
Aurinia Pharmaceuticals has $0 of total debt and $46.15M of cash and equivalents, a net cash position of $46.15M.
AUPH pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors